Copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Errors in Text. In the article “Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder” by Marcus et al published in the June issue of the ARCHIVES (2005;159:572-578), the sample sizes for both Ritalin LA and Metadate CD were inadvertently reversed in the “Selection of Study Cohorts” subsection of the “Methods” section on page 573. The correct numbers are Ritalin LA (n = 299) and Metadate CD (n = 287). The first sentence of the “Background Characteristics” subsection of the “Results” section on page 574 should read “Approximately 7 (70.1%) in 10 study patients were initially prescribed IR-MPH formulations.” Also, the mean durations of treatment and associated confidence intervals (CIs) for Metadate CD and Ritalin LA were inadvertently reversed in the “ER-MPH Formulations” subsection of the “Results” section on page 575. The correct numbers are Ritalin LA, 101.1 days (95% CI, 91.2-111.0 days) and Metadate CD, 113.0 days (95% CI, 100.9-125.1 days).
Errors in Text in: Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder. Arch Pediatr Adolesc Med. 2005;159(9):572-578. doi:10.1001/archpedi.159.9.875